摘要: Of the two clearly established drug oxidation polymorphisms, only one referred to as debrisoquine polymorphism affects many drugs. The known polymorphic substrates of mephenytoin hydroxylase are and mephobarbital. Relatively recently discovered propafenone, diltiazem, codeine. list contains 28 items. fate slightly less than half these is clinically affected in poor metabolizers, several latter drugs no longer marketed. There reasons why a failure metabolism may not alter sufficiently affect its clinical use. interest importance inhibition by inhibitors such quinidine some neuroleptics; also simultaneous use has led serious toxicity mutual metabolic inhibition. study polymorphisms been instructive for formal pharmacogenetics but understanding problems therapy patients without genetic defects.
springer.com
sci-hub.st 参考文章(102)
RR Meehan, JR Gosden, Rout D, ND Hastie, T Friedberg, M Adesnik, R Buckland, V Van Heyningen, J Fletcher, NK Spurr, J Sweeney, CR Wolf, Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. American Journal of Human Genetics. ,vol. 42, pp. 26- 37 ,(1988)
G. Clare Kahn, Alan R. Boobis, Donald S. Davies, Interindividual Differences in Monooxygenase Activities of Human Liver Individual Susceptibility to Genotoxic Agents in the Human Population. pp. 109- 153 ,(1984) , 10.1007/978-1-4613-2765-3_6
R. L. Smith, Polymorphism in Drug Metabolism — Implications for Drug Toxicity Archives of Toxicology. ,vol. 9, pp. 138- 146 ,(1986) , 10.1007/978-3-642-71248-7_16
Ronald W. Pero, Frederick J. De Serres, William Sheridan, Individual Susceptibility to Genotoxic Agents in the Human Population ,(1984)
B N La Du, C M Wyte, H W Eckerson, The human serum paraoxonase/arylesterase polymorphism. American Journal of Human Genetics. ,vol. 35, pp. 1126- 1138 ,(1983)
S D Hall, F P Guengerich, G R Wilkinson, R G Knodell, Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. Journal of Pharmacology and Experimental Therapeutics. ,vol. 241, pp. 1112- 1119 ,(1987)
M.S. Lennard, G.T. Tucker, H.F. Woods, The Polymorphic Oxidation of β-Adrenoceptor Antagonists Clinical Pharmacokinectics. ,vol. 11, pp. 1- 17 ,(1986) , 10.2165/00003088-198611010-00001
T. Inaba, M. Nakano, S. V. Otton, W. A. Mahon, W. Kalow, A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. Canadian Journal of Physiology and Pharmacology. ,vol. 62, pp. 860- 862 ,(1984) , 10.1139/Y84-144
Georges Gabris, Pierre Baumann, Michèle Jonzier-Perey, Paul Bosshart, Brigitte Woggon, Adrian Küpfer, N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients Biochemical Pharmacology. ,vol. 34, pp. 409- 410 ,(1985) , 10.1016/0006-2952(85)90063-2
M.S. Lennard, The polymorphic oxidation of beta-adrenoceptor antagonists Pharmacology & Therapeutics. ,vol. 41, pp. 461- 477 ,(1989) , 10.1016/0163-7258(89)90126-5